LCF Expectorant is a combination oral syrup formulated to alleviate symptoms associated with respiratory tract disorders characterized by excessive mucus production and bronchospasm. Each 5 ml dose contains Ambroxol 30 mg, Guaifenesin 100 mg, and Terbutaline 2.5 mg. Ambroxol acts as a mucolytic agent, facilitating the breakdown and clearance of viscous bronchial secretions, thereby improving mucociliary transport and easing expectoration. Guaifenesin functions as an expectorant, promoting the hydration of respiratory tract secretions to enhance mucus clearance and reduce cough frequency. Terbutaline, a selective beta-2 adrenergic receptor agonist, provides bronchodilation by relaxing bronchial smooth muscle, which helps relieve bronchospasm and improve airflow in obstructive airway conditions. LCF Expectorant is indicated for the symptomatic treatment of acute and chronic bronchitis, bronchial asthma, and other respiratory conditions accompanied by productive cough and bronchoconstriction. The combination of mucolytic, expectorant, and bronchodilator effects ensures comprehensive management of respiratory symptoms. Dosage and duration of therapy should be guided by clinical assessment and patient response. Use with caution in patients with cardiovascular disorders, hyperthyroidism, or diabetes. Adverse effects may include tremors, palpitations, gastrointestinal discomfort, and hypersensitivity reactions. Consult a healthcare professional before use.